Schreiber et al characterize a common inhibitory mechanism for ifenprodil and its derived compounds acting on GluN2B-containing N-methyl-D-aspartate receptors (NMDARs). These insights, generated through mutagenesis of the receptor binding site, chemical modifications of the compounds and structural modeling, may aid in the treatment of neurodegenerative diseases where GluN2B is involved.
- Julian A. Schreiber
- Dirk Schepmann
- Guiscard Seebohm
